undamentalytics Newsletter
Sign in

Accendra Health Inc (ACH) stock

Add to watchlist

Add holding +

NYSE: ACH NYSE Health Care Distributors Next results ~November 5, 2026

Accendra Health Inc is a US-listed company in the health care distributors industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Accendra Health Inc is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Accendra Health Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds63 adding, 66 cuttingOf 27 active managers that changed their stake, 14 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Accendra Health files

Where Accendra Health stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $2.65bn, down 3.3% on a year earlier, a steeper fall than the 0.0% decline a quarter earlier. Free-cash-flow margin fell to -13.8% from -3.6% a year earlier. Operating margin widened to 1.1% from -9.6%. It passes 0 of our 5 financial-health checks.

Our model value for Accendra Health is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 10, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Accendra Health Inc's trailing-twelve-month revenue fell 3.3% year on year, with a free-cash-flow margin of -13.8%.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 273.9% while net income grew 74.9%: a 349pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 10.7 points on a year ago.

Things to watch

  • Revenue shrinking. Revenue fell 3.3% over the last 12 months.
  • Burning cash. Free cash flow was -13.8% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 106% and a beta of 0.8 against the S&P 500.
  • Growth easing. The growth rate is 3.3 points lower than a quarter earlier.
  • Gross margin slipping. Gross margin is down 3.0 points on a year ago.
  • Heavily shorted. 14.6% of the shares available to trade are sold short (5.2 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 10, 2026
Earnings per share
-$0.19 against an average estimate of -$0.09: missed by 116.0%
Revenue
$613m, down 10.1% on a year earlier
Share reaction
-55.0% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Guidance given
revenue $2.45bn to $2.55bn (full year 2026); adjusted EBITDA $300m to $320m (full year 2026)
Next report
November 5, 2026; average EPS estimate -$0.09

Accendra Health's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.0%
  • 1 week+30.0%
  • 1 month-49.0%
  • This year-90.7%
  • 1 year-93.5%
  • 5 years-99.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$2.6B
Operating margin
1.1%
Net margin
-11.4%
EPS (TTM, diluted)
$-3.94

Growth

Revenue growth
−3.3%
Change in growth rate
−3.3 pts
Share count change
−0.5%

Cash

Free cash flow (TTM)
-$366M
FCF margin
-13.8%
Stock pay % of revenue
0.4%

Earnings

Last results
August 10, 2026

News & updates

Updated November 3, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Agreement
  3. Announcement
  4. Announcement
  5. Leadership
  6. Leadership
  7. Announcement
  8. Announcement
  9. Results
  10. Leadership
  11. Agreement
  12. Guidance
  13. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Accendra Health Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Accendra Health Inc as an operating company, with every model that fits that kind of business. Cost of equity 8%: the 10-year Treasury yield (4.9%) plus a beta of 0.67 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.5 ~$1.5–$1.7 Left out: out of range vs price (5.85x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Accendra Health Inc with Health Care Distributors in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$31.68$31.96$17.76$6.30$5.16$27.04$43.50$19.53$19.27$13.07$2.80$0.26
Market value$2.0bn$2.0bn$1.1bn$378m$313m$1.7bn$3.3bn$1.5bn$1.5bn$1.0bn$215m$20m
+ Net debt (− = net cash)$413m$384m$813m$1.6bn$1.5bn$943m$892m$2.4bn$1.9bn$1.8bn$1.8bn$1.7bn
Enterprise value$2.4bn$2.3bn$1.9bn$2.0bn$1.8bn$2.7bn$4.2bn$3.9bn$3.3bn$2.8bn$2.0bn$1.7bn
Multiples
Price / sales 0.2x0.2x0.1x0.0x0.0x0.2x0.3x0.1x0.6x0.4x0.1x0.0x
Price / earnings 19.0x17.9x14.6x——57.5x14.8x66.5x————
Price / free cash flow 7.9x11.7x48.1x5.3x2.5x5.9x39.5x8.9x2.6x———
EV / EBITDA 8.9x9.2x12.6x—9.5x8.9x9.1x10.5x9.7x—8.2x6.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

17 /100

Weak moat

How hard Accendra Health's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -2.6% of total assets over 10 years.

  • Pricing power 0 / 20

    Gross margin has been a median 15.7%, moving by 22.3 percentage points (standard deviation) across 10 years.

  • Durability 0 / 20

    Operating margin has been a median 1.0%; its worst year was -9.6%.

  • Cash conversion 9 / 20

    Free cash flow was positive in 8 of 10 years, at a median 1.3% of revenue.

  • Discipline 13 / 20

    The diluted share count rose 9.8% over five years; stock-based pay has been a median 0.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (22 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $617m and EPS of −$0.09 (range −$0.42 to $0.03) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.06 −106% $2.5bn −10%
Next $0.09 +235% $2.6bn +3%

Next year's EPS estimate has moved −87.7% in 90 days, across 5 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −116.5% on 90 days ago. In the last 30 days, 0 analysts raised Accendra Health Inc's forecast and 5 cut it.

Consensus EPS forecast Accendra Health Inc, last 90 days
−$0.20 $0.00 $0.20 $0.40 $0.60 $0.80 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.38 Current fiscal year, 60 days ago: −$0.04 Current fiscal year, 30 days ago: −$0.06 Current fiscal year, 7 days ago: −$0.06 Current fiscal year, Now: −$0.06 −$0.06 Next fiscal year, 90 days ago: $0.69 Next fiscal year, 60 days ago: $0.15 Next fiscal year, 30 days ago: $0.09 Next fiscal year, 7 days ago: $0.09 Next fiscal year, Now: $0.09 $0.09

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.38$0.69
60 days ago −$0.04$0.15
30 days ago −$0.06$0.09
7 days ago −$0.06$0.09
Now −$0.06$0.09

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.09 −$0.19 −116.0%
Mar 2026 −$0.10 −$0.04 +59.3%
Dec 2025 $0.22 $0.21 −5.1%
Sept 2025 $0.23 $0.25 +6.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 10, 2026
  • Revenue full year 2026 $2.45bn to $2.55bn
    “Revenue: $2.45 billion - $2.55 billion” source
  • Adjusted EBITDA full year 2026 $300m to $320m Non-GAAP
    “Adjusted EBITDA: $300 million - $320 million” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

5 analysts, Nov 2026
Buy00%
Hold360%
Sell240%

Monthly trend

  1. Nov 2026325
  2. Oct 2026325
  3. Sep 2026426

Counts of recommendations published by analysts covering Accendra Health Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.6%
of tradable shares
Days to cover
5.23
at average volume
Short interest, 1 month
+2%
to October 15, 2026
Held by institutions
84%
of shares
Held by insiders
7.3%
of shares
Employees
6,500
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −93.5%

$3.97 on October 31, 2025 to $0.26

ThenNowEffect
Revenue (last 12 months) $2.7bn $2.6bn −3.3%
P/S multiple 0.1x 0.0x −93.3%
Share count 77m 77m +0.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years −98.7%

$19.71 on November 3, 2023 to $0.26

ThenNowEffect
Revenue (last 12 months) $10.1bn $2.6bn −73.9%
P/S multiple 0.1x 0.0x −94.9%
Share count 76m 77m −1.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ACH+61%−55%−1%−32%−79%−91%
Industry peers (median)+16%+35%+24%+10%+45%+8%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ACH67%25%42%50%25%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ACH−37%−68%−46%−58%−84%−95%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from June 8, 2021 to October 26, 2026. Getting back needed a 24255% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.20 – $3.89
From 52-week high
−93.3%
vs 50-day average
−62.4%
vs 200-day average
−88.3%
Volatility (1 year)
106%
Beta vs S&P 500
0.76

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±20.8%
After a week
4 up, 8 down
typical move ±23.0%
After a month
4 up, 8 down
typical move ±24.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 10, 2026 −55.0% −0.3% −61.8% −61.8%
May 11, 2026 −10.6% +0.1% −23.5% −23.5%
February 19, 2026 +8.3% +0.5% +0.4% −18.7%
October 30, 2025 −23.9% −0.8% −40.2% −48.9%
August 11, 2025 −22.8% +0.9% −23.1% −22.7%
May 8, 2025 −9.7% +0.6% −8.6% +2.2%
February 28, 2025 +35.3% −0.2% +45.1% +31.1%
February 3, 2025 −35.8% 0.0% −40.6% −31.6%
November 4, 2024 −11.7% +1.0% +0.1% +10.3%
August 2, 2024 −9.4% −4.7% −7.6% −6.4%
July 23, 2024 +5.7% −2.4% +1.2% +3.4%
May 3, 2024 −21.6% +2.3% −24.0% −29.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Accendra Health Inc
-$5B $0 $5B $10B $15B FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $10.2B Revenue (TTM), FY23 Q4: $2.6B Revenue (TTM), FY24 Q1: $2.6B Revenue (TTM), FY24 Q2: $739.6M Revenue (TTM), FY24 Q3: -$1.2B Revenue (TTM), FY24 Q4: $4.7B Revenue (TTM), FY25 Q1: $2.7B Revenue (TTM), FY25 Q2: $2.7B Revenue (TTM), FY25 Q3: $2.7B Revenue (TTM), FY25 Q4: $2.8B Revenue (TTM), FY26 Q1: $2.7B Revenue (TTM), FY26 Q2: $2.6B $2.6B

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $10.2B
FY23 Q4 $2.6B
FY24 Q1 $2.6B
FY24 Q2 $739.6M
FY24 Q3 -$1.2B
FY24 Q4 $4.7B
FY25 Q1 $2.7B
FY25 Q2 $2.7B
FY25 Q3 $2.7B
FY25 Q4 $2.8B
FY26 Q1 $2.7B
FY26 Q2 $2.6B
Revenue growth, TTM YoY Accendra Health Inc
-100% 0% 100% 200% 300% FY23 Q1 FY23 Q4 FY24 Q4 FY26 Q2 Revenue growth, TTM YoY, FY23 Q1: 2.1% Revenue growth, TTM YoY, FY23 Q2: 2.6% Revenue growth, TTM YoY, FY23 Q3: 3.6% Revenue growth, TTM YoY, FY23 Q4: -74.4% Revenue growth, TTM YoY, FY24 Q1: -73.8% Revenue growth, TTM YoY, FY24 Q2: -92.7% Revenue growth, TTM YoY, FY24 Q4: 82.4% Revenue growth, TTM YoY, FY25 Q1: 2.8% Revenue growth, TTM YoY, FY25 Q2: 270.2% Revenue growth, TTM YoY, FY25 Q4: -40.7% Revenue growth, TTM YoY, FY26 Q1: -0.0% Revenue growth, TTM YoY, FY26 Q2: -3.3% -3.3%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q1 2.1%
FY23 Q2 2.6%
FY23 Q3 3.6%
FY23 Q4 -74.4%
FY24 Q1 -73.8%
FY24 Q2 -92.7%
FY24 Q4 82.4%
FY25 Q1 2.8%
FY25 Q2 270.2%
FY25 Q4 -40.7%
FY26 Q1 -0.0%
FY26 Q2 -3.3%
Operating margin (TTM) Accendra Health Inc
-20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -0.1% Operating margin (TTM), FY23 Q4: 5.2% Operating margin (TTM), FY24 Q1: 5.0% Operating margin (TTM), FY24 Q2: 18.8% Operating margin (TTM), FY24 Q3: -12.6% Operating margin (TTM), FY24 Q4: -4.6% Operating margin (TTM), FY25 Q1: -7.5% Operating margin (TTM), FY25 Q2: -9.6% Operating margin (TTM), FY25 Q3: -9.7% Operating margin (TTM), FY25 Q4: 1.0% Operating margin (TTM), FY26 Q1: 0.9% Operating margin (TTM), FY26 Q2: 1.1% 1.1%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -0.1%
FY23 Q4 5.2%
FY24 Q1 5.0%
FY24 Q2 18.8%
FY24 Q3 -12.6%
FY24 Q4 -4.6%
FY25 Q1 -7.5%
FY25 Q2 -9.6%
FY25 Q3 -9.7%
FY25 Q4 1.0%
FY26 Q1 0.9%
FY26 Q2 1.1%
FCF margin (TTM) Accendra Health Inc
-20% -10% 0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 5.0% FCF margin (TTM), FY23 Q4: 21.8% FCF margin (TTM), FY24 Q1: 13.1% FCF margin (TTM), FY24 Q2: 21.0% FCF margin (TTM), FY24 Q3: -1.1% FCF margin (TTM), FY24 Q4: -0.6% FCF margin (TTM), FY25 Q1: -0.3% FCF margin (TTM), FY25 Q2: -3.6% FCF margin (TTM), FY25 Q3: -11.5% FCF margin (TTM), FY25 Q4: -11.0% FCF margin (TTM), FY26 Q1: -11.5% FCF margin (TTM), FY26 Q2: -13.8% -13.8%

Source: SEC EDGAR filings. Retrieved October 26, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 5.0%
FY23 Q4 21.8%
FY24 Q1 13.1%
FY24 Q2 21.0%
FY24 Q3 -1.1%
FY24 Q4 -0.6%
FY25 Q1 -0.3%
FY25 Q2 -3.6%
FY25 Q3 -11.5%
FY25 Q4 -11.0%
FY26 Q1 -11.5%
FY26 Q2 -13.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 8,038 8,124 8,628 8,868 9,072 9,440 9,773 9,723 9,318 9,418 9,211 8,480 9,785 9,955 2,553 2,680 2,762 2,647
Gross profit 814 808 858 925 1,117 1,170 1,215 1,187 1,172 1,071 1,128 1,281 1,513 1,826 2,125 2,219 1,289 1,187
EBITDA 227 225 238 236 249 223 266 255 149 −250 190 297 459 372 344 −36 242 285
Operating income 201 196 204 197 198 160 200 200 89 −352 73 204 368 143 133 −218 27 29
Net income 105 111 115 109 111 67 103 109 73 −437 −62 30 222 22 −41 −363 −1,101 −302
Diluted EPS $1.67 $1.75 $1.81 $1.72 $1.76 $1.06 $1.65 $1.76 $1.20 −$7.28 −$1.03 $0.47 $2.94 $0.29 −$0.53 −$4.73 −$14.31 −$3.94
Growth (year on year)
Revenue +11.0% +1.1% +6.2% +2.8% +2.3% +4.1% +3.5% −0.5% −4.2% +1.1% −2.2% −7.9% +15.4% +1.7% −74.4% +5.0% +3.1% −3.3%
EBITDA +11.8% −0.6% +5.6% −0.5% +5.2% −10.3% +19.5% −4.3% −41.7% — — +56.7% +54.3% −19.1% −7.5% −110.6% — —
Operating income +11.4% −2.7% +3.9% −3.3% +0.7% −19.5% — −0.4% −55.3% — — — +80.5% −61.2% — −263.4% — —
Net income — — — — — — — — — — — — — −89.9% — — — —
Diluted EPS — — — — — — — — — — — — — −90.1% — — — —
Margins
Gross margin 10.1% 9.9% 9.9% 10.4% 12.3% 12.4% 12.4% 12.2% 12.6% 11.4% 12.3% 15.1% 15.5% 18.3% 83.3% 82.8% 46.7% 44.8%
EBITDA margin 2.8% 2.8% 2.8% 2.7% 2.7% 2.4% 2.7% 2.6% 1.6% −2.7% 2.1% 3.5% 4.7% 3.7% 13.5% −1.4% 8.8% 10.8%
Operating margin 2.5% 2.4% 2.4% 2.2% 2.2% 1.7% 2.1% 2.1% 1.0% −3.7% 0.8% 2.4% 3.8% 1.4% 5.2% −8.1% 1.0% 1.1%
Net margin 1.3% 1.4% 1.3% 1.2% 1.2% 0.7% 1.1% 1.1% 0.8% −4.6% −0.7% 0.4% 2.3% 0.2% −1.6% −13.5% −39.8% −11.4%
Free-cash-flow margin 2.5% 1.4% 0.5% 2.4% 1.2% −0.6% 2.6% 1.7% 0.2% 0.8% 1.3% 3.4% 0.9% 1.7% 22.3% −0.3% −10.6% −13.5%
Cash flow
Cash from operations 218 143 68 219 141 −4 270 188 57 116 166 339 124 325 741 161 −102 −180
Capital spending 20 31 25 10 28 48 21 20 35 45 42 50 41 158 172 170 191 177
Free cash flow 198 112 43 209 112 −52 250 167 22 71 124 289 83 167 568 −9 −293 −357
Stock-based pay 7 6 6 6 6 8 11 12 12 16 16 20 25 21 14 17 13 11
Free cash flow after stock pay 191 106 38 203 106 −60 238 155 10 54 108 269 58 146 554 −25 −306 −368
Balance sheet
Cash 96 159 136 98 102 57 161 185 105 66 67 83 56 69 243 28 282 8
Total debt 208 211 215 218 216 614 574 569 917 1,677 1,560 1,026 948 2,501 2,098 1,841 2,050 1,718
Net debt (negative = net cash) 112 52 79 120 114 557 413 384 813 1,610 1,493 943 892 2,431 1,854 1,814 1,768 1,710
Diluted shares 62m 63m 63m 63m 63m 62m 62m 61m 60m 60m 61m 64m 75m 76m 77m 77m 77m 77m
Returned to shareholders
Dividends 38 45 51 56 61 63 64 63 63 48 5 1 1 0 0 — — —
Buybacks — — 16 15 19 10 20 71 5 0 — — — — — — 10 —
Total returned 38 45 67 71 80 73 84 134 68 48 5 1 1 0 0 — 10 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

0 of 5 checks passed · June 30, 2026
What it owns · $2.1bn
Short-term assets $271mLonger-term assets $1.8bn
What it owes, and who funded it · $2.7bn
Short-term liabilities $666mLonger-term liabilities $2.0bnShareholders' equity $-551m
  • Short-term assets cover short-term liabilities $271m of assets due within a year against $666m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $271m short-term assets against $2.0bn of longer-dated liabilities.
  • More cash than debt $8m of cash against $1.7bn of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$180m of operating cash flow against $1.7bn of debt.
  • Operating profit covers interest at least five times over Operating income of $29m against $124m of interest.

From Accendra Health Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q1 TTM
Buybacks (TTM)
$8.7M
Buybacks, last 3 fiscal years
$15.2M
Diluted share count
−0.5%
year over year
Total shareholder yield
43.4%
dividends 0.0% + buybacks 43.4% of market value
Sales & admin spending
39.1%
of revenue

Competitors: side by side with peers

Closest by revenue in health care distributors
Last 12 months unless stated ACH YI HSIC COSM COR MCK Median
Revenue, last 12 months $2.6bn $1.7bn $13.6bn $74m $332.8bn $411.0bn $2.6bn
Revenue growth, last 12 months −3.3% −12.7% 6.5% 33.8% 5.1% 8.8% 5.1%
Revenue growth, 3-year average −36.1% — 2.6% 14.8% 9.4% 13.1% 9.4%
Revenue growth, latest quarter −10.1% — 6.7% 28.8% 5.1% 7.7% 6.7%
Gross margin 44.8% 5.8% 31.3% 10.3% 4.0% 3.6% 10.3%
Operating margin 1.1% −0.0% 5.0% −24.9% 0.9% 1.6% 0.9%
Operating margin, 3-year average 3.5% −10.6% 4.8% −29.5% 0.9% 1.3% 1.1%
Net margin −11.4% −0.5% 3.0% −33.1% 0.8% 1.1% −0.5%
Cash from operations / revenue −6.8% 0.9% 5.1% −13.3% 1.4% 1.7% 0.9%
Free-cash-flow margin −13.8% 0.9% 4.2% −13.5% 1.2% 1.6% 0.9%
Free-cash-flow margin, 3-year average 1.2% −9.0% 3.8% −12.4% 1.0% 1.4% 1.1%
Stock pay / revenue 0.4% 0.1% 0.3% 2.3% 0.0% 0.1% 0.2%
Change in share count −0.5% 1.3% −6.1% 79.3% −0.5% −3.4% −0.5%

Median of all 7 companies we cover in health care distributors. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Diabetes Product $783M 28.4% ▲ 0.8%
Sleep Therapy Product $740M 26.8% ▲ 5.3%
Home Respiratory Therapy Product $433M 15.7% ▼ 0.7%
Other $288M 10.4% ▲ 7.4%
Ostomy $213M 7.7% ▲ 8.6%
Wound Care $189M 6.8% ▼ 2.0%
Urology $116M 4.2% ▲ 8.3%

From Accendra Health Inc's 10-K filed February 20, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$213M
Institutions reporting
138
Shares held vs prior quarter
▼ 1.1%
Positions opened / closed
20 / 20

Top buyers and sellers, Q2 2026: 63 institutions bought and 66 sold ; the biggest buyer was Marshall Wace, LLP (+822K shares) and the biggest seller Dimensional Fund Advisors LP (−966K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Coliseum Capital Management, LLC $44.8M 13.1M 21.0% 0.0%
Blackrock, Inc. $18.8M 5.5M 8.8% ▲ 5.1%
Bank Of America Corp $12.9M 3.8M 6.1% ▲ 10.8%
Vanguard Capital Management LLC $10.6M 3.1M 5.0% ▼ 5.9%
D. E. Shaw & Co., Inc. $10.5M 3.1M 4.9% ▼ 7.0%
Charles Schwab Investment Management Inc $9.9M 2.9M 4.6% ▼ 20.6%
Invenomic Capital Management LP $9.6M 2.8M 4.5% ▼ 16.5%
Marshall Wace, LLP $8.8M 2.6M 4.1% ▲ 46.7%
Paradigm Capital Management Inc $8.7M 2.5M 4.1% ▲ 42.0%
Vanguard Portfolio Management LLC $6.9M 2.0M 3.3% ▼ 23.4%
Dana Investment Advisors, Inc. $6.7M 1.9M 3.1% ▲ 30.9%
Geode Capital Management, LLC $6.4M 1.9M 3.0% ▲ 2.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Accendra Health Inc's complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 29, 2026 estimated from the company's past filing pattern, not announced

  • August 10, 2026
  • May 11, 2026
  • February 19, 2026
  • October 30, 2025
  • August 11, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Accendra Health Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Accendra Health Inc in brief

What does Accendra Health Inc do?
Accendra Health Inc is a US-listed company in the health care distributors industry. Its financial year ends in December.
What is Accendra Health Inc's stock ticker?
Accendra Health Inc trades under the ticker ACH on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Accendra Health Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Accendra Health Inc reported revenue of $2.6B, 3.3% lower than a year earlier, according to its SEC filings.
What is Accendra Health Inc's free cash flow?
Accendra Health Inc's free-cash-flow margin is -13.8% of revenue over the trailing twelve months.
Who are Accendra Health Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Coliseum Capital Management, LLC, Blackrock, Inc. and Bank Of America Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Accendra Health Inc buying back stock, and does it pay a dividend?
Accendra Health Inc spent $8.7M on share repurchases over the trailing twelve months, and its diluted share count fell 0.5% over the year.
What is Accendra Health Inc's market cap?
On November 2, 2026, Accendra Health Inc's market capitalisation was about $19.9M and net debt of $1.7B. Market figures come from third-party market data and may be delayed.
Who are Accendra Health Inc's competitors?
In our Health Care Distributors peer group, the companies closest to Accendra Health Inc are 111, Inc., Henry Schein, Cosmos Health Inc., Cencora and McKesson. The side-by-side comparison below sets their revenue, margins and growth against Accendra Health Inc's.
When is Accendra Health Inc's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Accendra Health Inc announces its own schedule.